보고서 요약(국문)

보고서 개요
글로벌 유방암 액체 생검 시장은 2023년 16억 달러에 달했으며, 2024년부터 2031년까지 연평균 23.2%의 성장률을 기록하며 2031년에는 79억 8천만 달러에 이를 것으로 예상됩니다.
액체 생검은 혈액, 소변 또는 기타 체액 샘플을 이용하여 종양에서 암세포를 찾거나 종양 세포가 체액으로 방출하는 DNA, RNA 또는 기타 분자 조각을 검출하는 실험실 검사입니다. 액체 생검을 통해 시간에 따라 여러 샘플을 채취할 수 있으므로, 의사는 종양에서 어떤 유전적 또는 분자적 변화가 일어나고 있는지 파악하는 데 도움을 받을 수 있습니다. 액체 생검은 암을 조기에 발견하는 데 도움이 될 수 있으며, 치료 계획을 수립하거나 치료 효과를 평가하거나 암이 재발했는지 여부를 확인하는 데에도 사용될 수 있습니다.
액체 생검 샘플은 순환 종양 세포(CTC), 세포 유리 핵산, 엑소좀 또는 종양 유래 혈소판과 같은 다양한 생물학적 매트릭스로 구성됩니다. 최근 기술 및 분자적 발전, 특히 많은 경우 미세유체 기술의 활용으로 액체 생검 성분의 정제 및 분석 능력이 크게 향상되었습니다.
시장 동향: 성장 동력
유방암 발병률 증가
유방암 액체 생검 시장의 수요는 여러 요인에 의해 주도되고 있습니다. 유방암 발병률의 증가가 시장 성장을 견인하고 있습니다.
또한, 사람들의 인식 제고와 기술 발전으로 치료 수요가 증가할 것으로 예상됩니다. 예를 들어, uicc.org에 따르면 유방암은 전 세계 여성에게 가장 흔하게 진단되는 암이며, 157개국에서 여성에게 가장 흔하게 진단되는 암으로 전체 암 사례의 4분의 1을 차지합니다. 남녀 모두에게 두 번째로 흔한 암이며, 여성의 암 사망 원인 1위입니다. 2022년에는 약 230만 건의 새로운 유방암 사례가 발생할 것으로 추정되며, 이는 전 세계적으로 진단되는 남녀 암 사례의 약 9분의 1에 해당합니다. 2022년에는 유방암으로 인해 약 669,418명이 사망했으며, 이 중 상당수가 저개발 국가에서 발생했습니다.
또한 breastcancer.org에 따르면, 유방암 환자의 약 66%는 암이 유방 밖으로 전이되기 전, 치료가 가장 용이한 국소 단계에서 진단됩니다. 현재 미국에는 400만 명이 넘는 여성이 유방암 병력을 가지고 있습니다.
더욱이, 2023년 2월 WHO가 발표한 자료에 따르면 매년 230만 건 이상의 유방암 사례가 발생하며, 이는 성인에게 가장 흔한 암입니다. 95%의 국가에서 유방암은 여성 암 사망 원인 1위 또는 2위입니다. 그러나 유방암 생존율은 국가 간, 그리고 국가 내에서도 매우 불평등하며, 유방암 및 자궁경부암으로 인한 사망의 거의 80%가 저소득 및 중소득 국가에서 발생합니다.

제약 요인
액체 생검과 관련된 높은 비용, 숙련된 전문가 부족, 새로운 치료법 승인을 위한 엄격한 규제 요건 등의 요인이 시장 성장을 저해할 것으로 예상됩니다.
시장 세분화 분석
전 세계 유방암 액체 생검 시장은 제품 유형, 순환 바이오마커, 적용 분야, 최종 사용자 및 지역별로 세분화됩니다.
순환 종양 세포(CTC) 부문은 전 세계 유방암 액체 생검 시장 점유율의 약 47.9%를 차지했습니다.
순환 종양 세포 부문은 예측 기간 동안 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 이 부문에서는 기술 발전과 민간 제조업체의 연구 자금 증가가 시장 성장을 견인할 것입니다.
순환 종양 세포(CTC)를 이용한 액체 생검은 임상 적용 및 기초 암 연구에서 큰 잠재력을 가지고 있습니다. 최소 침습 기술인 액체 생검은 체액에서 직접 암 바이오마커를 검출할 수 있도록 합니다. 이러한 바이오마커 중 CTC(순환 종양 세포), 세포 유리 DNA(cfDNA), RNA는 종양의 유전적 특성을 역동적으로 보여줍니다. 이 혁신적인 접근 방식은 조기 암 진단, 질병 진행 모니터링, 맞춤형 치료 전략 수립에 유망한 가능성을 제시합니다.
CTC는 이제 전이 과정에서 중요한 역할을 하는 것으로 인식되고 있습니다. CTC의 검출 및 분석은 액체 생검 기술 개발의 길을 열었으며, 기존의 조직 생검에 비해 최소 침습적인 대안을 제공합니다. 이 혁신적인 접근 방식은 종양 역학에 대한 이해를 획기적으로 바꾸어 실시간 모니터링을 가능하게 하고 종양 이질성, 치료 반응, 질병 진행에 대한 통찰력을 제공합니다.
시장 지역 분석
북미는 전 세계 유방암 액체 생검 시장 점유율의 약 42.8%를 차지했습니다.
북미 지역은 예측 기간 동안 가장 큰 시장 점유율을 유지할 것으로 예상됩니다. 이 지역의 유방암 발병률 증가와 사람들의 인식 제고가 시장 성장을 견인하고 있습니다.

예를 들어, breastcancer.org에 따르면 미국 여성의 약 13%(약 8명 중 1명)가 평생 동안 침습성 유방암에 걸릴 것으로 예상됩니다. 최근 몇 년 동안 발병률은 매년 0.5%씩 소폭 증가했습니다. 유방암은 여전히 미국 여성에서 폐암 다음으로 두 번째로 흔한 암 관련 사망 원인입니다. 유방암은 피부암 다음으로 미국 여성에게 가장 흔하게 진단되는 암입니다. 매년 여성에게 새로 진단되는 모든 암의 약 30%가 유방암입니다. 현재 미국에는 유방암 병력이 있는 여성이 400만 명이 넘습니다.
또한 2023년 6월, Labcorp는 암 관련 바이오마커를 검출하는 액체 생검을 출시했습니다. 플라즈마 포커스 액체 생검은 일반적인 혈액 채취만으로 검사를 진행할 수 있습니다. 이 검사는 종양 세포가 혈류로 방출하는 세포 유리 DNA(cfDNA) 조각을 샘플에서 분석하여 특정 환자에게 가장 효과적인 암 치료법에 대한 통찰력을 제공할 수 있습니다.

시장 세분화
제품 유형별
시약 및 키트
기기
순환 바이오마커별
순환 종양 세포(CTC)
순환 세포 유리 DNA(cfDNA)
세포외 소포(EV)
기타
응용 분야별
조기 검진
치료 선택
최종 사용자별
병원
진단 센터
연구 및 교육 기관
기타
지역별
북미
미국
캐나다
멕시코
유럽
독일
영국
프랑스
스페인
이탈리아
기타 유럽
남미
브라질
아르헨티나
기타 남미
아시아 태평양
중국
인도
일본
한국
기타 아시아 태평양
중동 및 아프리카
시장 경쟁 환경
전 세계 유방암 액체 생검 시장의 주요 글로벌 업체로는 F. 등이 있습니다. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, Agilent Technologies Inc., Merck KGaA, Cell Signaling Technology Inc., Medtronic, Bio-Rad Laboratories Inc., ExoDx, Biocept Inc. 등이 주요 기업입니다.
주요 개발 사항
2023년 9월, nRichDX®는 최대 40mL의 전혈 샘플에서 순환 종양 세포(CTC)를 특이적으로 분리하는 새로운 RUO 표지 CTC 농축 키트를 출시하여 연구자들이 액체 생검 분석 연구 개발을 발전시키는 데 도움을 주었습니다.
보고서 구매 이유
제품 유형, 순환 바이오마커, 응용 분야, 최종 사용자 및 지역별 글로벌 유방암 액체 생검 시장 세분화를 시각화하고 주요 상업적 자산 및 기업을 파악하기 위해
트렌드 분석 및 공동 개발을 통해 상업적 기회를 식별하기 위해
모든 세그먼트를 포함한 글로벌 유방암 액체 생검 시장의 다양한 데이터 포인트가 담긴 Excel 데이터 시트

보고서 구매 이유 PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 결과를 담고 있습니다.
주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑은 Excel 파일로 제공됩니다.
글로벌 유방암 액체 생검 시장 보고서는 약 51개의 표, 54개의 그림, 그리고 181페이지 분량으로 구성됩니다.
대상 고객 (2024년 기준)
제조업체/구매자
산업 투자자/투자 은행가
연구 전문가
신흥 기업

보고서 요약(영어 원문)

Report Overview
The Global Breast Cancer Liquid Biopsy Market reached US$ 1.6 billion in 2023 and is expected to reach US$ 7.98 billion by 2031, growing at a CAGR of 23.2% during the forecast period 2024-2031.
A liquid biopsy is a laboratory test done on a sample of blood, urine, or other body fluid to look for cancer cells from a tumor or small pieces of DNA, RNA, or other molecules released by tumor cells into a person’s body fluids. Liquid biopsy allows multiple samples to be taken over time, which may help doctors understand what kind of genetic or molecular changes are taking place in a tumor. A liquid biopsy may be used to help find cancer at an early stage. It may also be used to help plan treatment or to find out how well treatment is working or if cancer has come back.
It is composed of different biological matrices such as circulating tumor cells (CTCs), cell-free nucleic acids, exosomes or tumors "educated platelets." Recent technological and molecular advances, greatly facilitated by the use of microfluidics in many cases, have permitted large progress in both the ability to purify and analyze liquid biopsy components.
Market Dynamics: Drivers
Increasing prevalence of breast cancer
The demand for the breast cancer liquid biopsy market is driven by multiple factors. The rising prevalence of breast cancer propels the market growth.
Furthermore, the demand for treatment will be fueled by the increase in awareness among people and technological advancements. For instance, according to uicc.org, Breast cancer is the most diagnosed cancer among women worldwide and is the most diagnosed cancer in women in 157 countries, accounting for 1 in 4 cancer cases. It is the second most frequent cancer amongst both sexes and is the leading cause of death from cancer in women. With the estimated 2.3 million new cases of breast cancer in 2022, roughly one in every 9 cancers for both sexes diagnosed globally was breast cancer. In 2022, there were an estimated 669,418 deaths from breast cancer, with a disproportionate number of these deaths occurring in low-resource settings.
Moreover, according to breastcancer.org, About 66% of breast cancer cases are diagnosed at a localized stage before cancer has spread outside of the breast when it is easiest to treat. There are currently more than four million women with a history of breast cancer in the US.
Moreover, according to an article posted by WHO in February 2023, there are more than 2.3 million cases of breast cancer that occur each year, which makes it the most common cancer among adults. In 95% of countries, breast cancer is the first or second leading cause of female cancer deaths. Yet, survival from breast cancer is widely inequitable between and within countries nearly 80% of deaths from breast and cervical cancer occur in low- and middle-income countries.
Restraints
Factors such as high costs associated with liquid biopsy, the shortage of skilled professionals, and stringent regulatory requirements for the approval of new treatments are expected to hamper the market.
Market Segment Analysis
The global breast cancer liquid biopsy market is segmented based on product type, circulating biomarkers, application, end-user, and region.
The segment circulating tumor cells (CTCs) accounted for approximately 47.9% of the global breast cancer liquid biopsy market share
The circulating tumor cells segment is expected to hold the largest market share over the forecast period. In this segment, the technological advancements, and rising funds for private manufacturers for research work would drive this market.
Circulating tumor cells (CTCs) as a liquid biopsy have great potential in clinical applications and basic cancer research. Liquid biopsy, a minimally invasive technique, allows for the detection of cancer biomarkers directly from bodily fluids. Among these biomarkers, CTCs, cell-free DNA (cfDNA), and RNA provide a dynamic glimpse into the tumor’s genetic landscape. This revolutionary approach offers promising avenues for early cancer detection, monitoring disease progression, and tailoring personalized treatment strategies.
CTCs are now recognized as crucial players in the metastatic process. Their detection and analysis have paved the way for the development of liquid biopsy techniques, offering a minimally invasive alternative to traditional tissue biopsies. This innovative approach has revolutionized our understanding of tumor dynamics, enabling real-time monitoring and providing insights into tumor heterogeneity, treatment response, and disease progression.
Market Geographical Analysis
North America accounted for approximately 42.8% of the global breast cancer liquid biopsy market share
North America region is expected to hold the largest market share over the forecast period. The rising incidence of breast cancer, and growing awareness among people, in this region, help to propel the market.
For instance, according to breastcancer.org, approximately 13% (about one in eight) of U.S. women will develop invasive breast cancer in the course of their life. In recent years, incidence rates have increased slightly by 0.5% per year. Breast cancer is still one of the leading causes of cancer-related death in U.S. women, second only to lung cancer. Breast cancer is the most commonly diagnosed cancer among U.S. women after skin cancers. Each year, about 30% of all newly diagnosed cancers in women are breast cancer. There are currently more than four million women with a history of breast cancer in the US.
Moreover in June 2023, Labcorp launched liquid biopsy to detect cancer-related biomarkers. The Plasma Focus liquid biopsy requires only a standard blood draw to run. It looks through the sample for bits of cell-free DNA (cfDNA) that are released by tumor cells into the bloodstream and that may offer insights into the cancer treatments that’ll work most effectively for a specific patient.
Market Segmentation
By Product Type
Reagents & Kits
Instruments
By Circulating Biomarkers
Circulating Tumor Cells (CTCs)
Circulating Cell-free DNA (cfDNA)
Extracellular Vesicles (EVs)
Others
By Application
Early Screening
Treatment Selection
By End-User
Hospitals
Diagnostic Centers
Research and Educational Institutions
Others
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Asia-Pacific
China
India
Japan
South Korea
Rest of Asia-Pacific
Middle East and Africa
Market Competitive Landscape
The major global players in the global breast cancer liquid biopsy market include F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, Agilent Technologies Inc., Merck KGaA, Cell Signaling Technology Inc., Medtronic, Bio-Rad Laboratories Inc., ExoDx, and Biocept Inc. among others.
Key Developments
On September 2023, nRichDX® launched its new RUO-labeled CTC enrichment kit that uniquely isolates Circulating Tumor Cells (CTCs) from up to 40mL of whole blood samples to help researchers advance liquid biopsy assay research and development.
Why Purchase the Report?
To visualize the global breast cancer liquid biopsy market segmentation based on product type, circulating biomarkers, application, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development
Excel data sheet with numerous data points of global breast cancer liquid biopsy market level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping is available in Excel consisting of key products of all the major players.
The global breast cancer liquid biopsy market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Product Type
3.2. Snippet by Circulating Biomarkers
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Prevalence of Breast Cancer
4.1.1.2. Increasing Awareness Among People
4.1.1.3. Technological Advancements
4.2. Restraints
4.2.1. High Costs Associated with Liquid Biopsy
4.2.2. Shortage of Skilled Professionals
4.2.3. Stringent Regulatory Requirements
4.3. Opportunity
4.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet Needs
5.6. PESTEL Analysis
5.7. Patent Analysis
5.8. SWOT Analysis
6. By Product Type
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
6.1.2. Market Attractiveness Index, By Product Type
6.2. Reagents and Kits*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Instruments
7. By Circulating Biomarkers
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarkers
7.1.2. Market Attractiveness Index, By Circulating Biomarkers
7.2. Circulating Tumor Cells (CTCs)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Circulating Cell-free DNA (cfDNA)
7.4. Extracellular Vesicles
7.5. Others
8. By Application
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. Early Screening*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Treatment Selection
9. By End-User
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Diagnostic Centers
9.4. Research and Educational Institutions
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarkers
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.7.1. The U.S.
10.2.7.2. Canada
10.2.7.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarkers
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.7.1. Germany
10.3.7.2. UK
10.3.7.3. France
10.3.7.4. Italy
10.3.7.5. Spain
10.3.7.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulating Biomarkers
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.7.1. Brazil
10.4.7.2. Argentina
10.4.7.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulatory Biomarkers
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.7.1. China
10.5.7.2. India
10.5.7.3. Japan
10.5.7.4. South Korea
10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Circulatory Biomarkers
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. F. Hoffmann-La Roche Ltd. *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Thermo Fisher Scientific Inc.
12.3. Abbott
12.4. Agilent Technologies Inc.
12.5. Merck KGaA
12.6. Cell Signaling Technology Inc.
12.7. Medtronic
12.8. Bio-Rad Laboratories Inc.
12.9. ExoDx
12.10. Biocept Inc. (*LIST NOT EXHAUSTIVE)
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

F. Hoffmann-La Roche Ltd., 4.	Key Developments, Thermo Fisher Scientific Inc., Abbott, Agilent Technologies Inc., Merck KGaA, Cell Signaling Technology Inc., Medtronic, Bio-Rad Laboratories Inc., ExoDx

표 목록 (Tables)

List of Tables

Table 1 Global Breast Cancer Liquid Biopsy Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Breast Cancer Liquid Biopsy Market Value, By Circulating Biomarkers, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Breast Cancer Liquid Biopsy Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Breast Cancer Liquid Biopsy Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Breast Cancer Liquid Biopsy Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Breast Cancer Liquid Biopsy Market Value, By Product Type, 2023, 2027 & 2031 (US$ Million)

Table 7 Global Breast Cancer Liquid Biopsy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 8 Global Breast Cancer Liquid Biopsy Market Value, By Circulating Biomarkers, 2023, 2027 & 2031 (US$ Million)

Table 9 Global Breast Cancer Liquid Biopsy Market Value, By Circulating Biomarkers, 2022-2031 (US$ Million)

Table 10 Global Breast Cancer Liquid Biopsy Market Value, By Application, 2023, 2027 & 2031 (US$ Million)

Table 11 Global Breast Cancer Liquid Biopsy Market Value, By Application, 2022-2031 (US$ Million)

Table 12 Global Breast Cancer Liquid Biopsy Market Value, By End-User, 2023, 2027 & 2031 (US$ Million)

Table 13 Global Breast Cancer Liquid Biopsy Market Value, By End-User, 2022-2031 (US$ Million)

Table 14 Global Breast Cancer Liquid Biopsy Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 15 Global Breast Cancer Liquid Biopsy Market Value, By Region, 2022-2031 (US$ Million)

Table 16 North America Breast Cancer Liquid Biopsy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 17 North America Breast Cancer Liquid Biopsy Market Value, By Circulating Biomarkers, 2022-2031 (US$ Million)

Table 18 North America Breast Cancer Liquid Biopsy Market Value, By Application, 2022-2031 (US$ Million)

Table 19 North America Breast Cancer Liquid Biopsy Market Value, By End-User, 2022-2031 (US$ Million)

Table 20 North America Breast Cancer Liquid Biopsy Market Value, By Country, 2022-2031 (US$ Million)

Table 21 South America Breast Cancer Liquid Biopsy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 22 South America Breast Cancer Liquid Biopsy Market Value, By Circulating Biomarkers, 2022-2031 (US$ Million)

Table 23 South America Breast Cancer Liquid Biopsy Market Value, By Application, 2022-2031 (US$ Million)

Table 24 South America Breast Cancer Liquid Biopsy Market Value, By End-User, 2022-2031 (US$ Million)

Table 25 South America Breast Cancer Liquid Biopsy Market Value, By Country, 2022-2031 (US$ Million)

Table 26 Europe Breast Cancer Liquid Biopsy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 27 Europe Breast Cancer Liquid Biopsy Market Value, By Circulating Biomarkers, 2022-2031 (US$ Million)

Table 28 Europe Breast Cancer Liquid Biopsy Market Value, By Application, 2022-2031 (US$ Million)

Table 29 Europe Breast Cancer Liquid Biopsy Market Value, By End-User, 2022-2031 (US$ Million)

Table 30 Europe Breast Cancer Liquid Biopsy Market Value, By Country, 2022-2031 (US$ Million)

Table 31 Asia-Pacific Breast Cancer Liquid Biopsy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 32 Asia-Pacific Breast Cancer Liquid Biopsy Market Value, By Circulating Biomarkers, 2022-2031 (US$ Million)

Table 33 Asia-Pacific Breast Cancer Liquid Biopsy Market Value, By Application, 2022-2031 (US$ Million)

Table 34 Asia-Pacific Breast Cancer Liquid Biopsy Market Value, By End-User, 2022-2031 (US$ Million)

Table 35 Asia-Pacific Breast Cancer Liquid Biopsy Market Value, By Country, 2022-2031 (US$ Million)

Table 36 Middle East and Africa Breast Cancer Liquid Biopsy Market Value, By Product Type, 2022-2031 (US$ Million)

Table 37 Middle East and Africa Breast Cancer Liquid Biopsy Market Value, By Circulating Biomarkers, 2022-2031 (US$ Million)

Table 38 Middle East and Africa Breast Cancer Liquid Biopsy Market Value, By Application, 2022-2031 (US$ Million)

Table 39 Middle East and Africa Breast Cancer Liquid Biopsy Market Value, By End-User, 2022-2031 (US$ Million)

Table 40 Middle East and Africa Breast Cancer Liquid Biopsy Market Value, By Country, 2022-2031 (US$ Million)

Table 41 F. Hoffmann-La Roche Ltd: Overview

Table 42 F. Hoffmann-La Roche Ltd: Product Portfolio

Table 43 F. Hoffmann-La Roche Ltd: Key Developments

Table 44 Thermo Fisher Scientific Inc.: Overview

Table 45 Thermo Fisher Scientific Inc.: Product Portfolio

Table 46 Thermo Fisher Scientific Inc.: Key Developments

Table 47 Abbott: Overview

Table 48 Abbott: Product Portfolio

Table 49 Abbott: Key Developments

Table 50 Agilent Technologies Inc.: Overview

Table 51 Agilent Technologies Inc.: Product Portfolio

Table 52 Agilent Technologies Inc.: Key Developments

Table 53 Merck KGaA: Overview

Table 54 Merck KGaA: Product Portfolio

Table 55 Merck KGaA: Key Developments

Table 56 Cell Signaling Technology Inc.: Overview

Table 57 Cell Signaling Technology Inc.: Product Portfolio

Table 58 Cell Signaling Technology Inc.: Key Developments

Table 59 Medtronic: Overview

Table 60 Medtronic: Product Portfolio

Table 61 Medtronic: Key Developments

Table 62 Bio-Rad Laboratories Inc.: Overview

Table 63 Bio-Rad Laboratories Inc.: Product Portfolio

Table 64 Bio-Rad Laboratories Inc.: Key Developments

Table 65 ExoDx: Overview

Table 66 ExoDx: Product Portfolio

Table 67 ExoDx: Key Developments

Table 68 Biocept Inc.: Overview

Table 69 Biocept Inc.: Product Portfolio

Table 70 Biocept Inc.: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 2 Global Breast Cancer Liquid Biopsy Market Share, By Product Type, 2023 & 2031 (%)

Figure 3 Global Breast Cancer Liquid Biopsy Market Share, By Circulating Biomarkers, 2023 & 2031 (%)

Figure 4 Global Breast Cancer Liquid Biopsy Market Share, By Application, 2023 & 2031 (%)

Figure 5 Global Breast Cancer Liquid Biopsy Market Share, By End-User, 2023 & 2031 (%)

Figure 6 Global Breast Cancer Liquid Biopsy Market Share, By Region, 2023 & 2031 (%)

Figure 7 Global Breast Cancer Liquid Biopsy Market Y-o-Y Growth, By Product Type, 2023-2031 (%)

Figure 8 Reagents & Kits Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 9 Instruments Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 10 Global Breast Cancer Liquid Biopsy Market Y-o-Y Growth, By Circulating Biomarkers, 2023-2031 (%)

Figure 11 Circulating Tumor Cells (CTCs) Circulating Biomarkers in Global Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 12 Circulating Cell-free DNA (cfDNA) Circulating Biomarkers in Global Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 13 Extracellular Vesicles (EVs) Circulating Biomarkers in Global Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 14 Others Circulating Biomarkers in Global Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 15 Global Breast Cancer Liquid Biopsy Market Y-o-Y Growth, By Application, 2023-2031 (%)

Figure 16 Early Screening Application in Global Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 17 Treatment Selection Application in Global Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 18 Global Breast Cancer Liquid Biopsy Market Y-o-Y Growth, By End-User, 2023-2031 (%)

Figure 19 Hospitals End-User in Global Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 20 Diagnostic Centers End-User in Global Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 21 Research and Educational Institutions End-User in Global Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 22 Global Breast Cancer Liquid Biopsy Market Y-o-Y Growth, By Region, 2023-2031 (%)

Figure 23 North America Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 24 North America Breast Cancer Liquid Biopsy Market Share, By Product Type, 2023 & 2031 (%)

Figure 25 North America Breast Cancer Liquid Biopsy Market Share, By Circulating Biomarkers, 2023 & 2031 (%)

Figure 26 North America Breast Cancer Liquid Biopsy Market Share, By Application, 2023 & 2031 (%)

Figure 27 North America Breast Cancer Liquid Biopsy Market Share, By End-User, 2023 & 2031 (%)

Figure 28 North America Breast Cancer Liquid Biopsy Market Share, By Country, 2023 & 2031 (%)

Figure 29 South America Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 30 South America Breast Cancer Liquid Biopsy Market Share, By Product Type, 2023 & 2031 (%)

Figure 31 South America Breast Cancer Liquid Biopsy Market Share, By Circulating Biomarkers, 2023 & 2031 (%)

Figure 32 South America Breast Cancer Liquid Biopsy Market Share, By Application, 2023 & 2031 (%)

Figure 33 South America Breast Cancer Liquid Biopsy Market Share, By End-User, 2023 & 2031 (%)

Figure 34 South America Breast Cancer Liquid Biopsy Market Share, By Country, 2023 & 2031 (%)

Figure 35 Europe Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 36 Europe Breast Cancer Liquid Biopsy Market Share, By Product Type, 2023 & 2031 (%)

Figure 37 Europe Breast Cancer Liquid Biopsy Market Share, By Circulating Biomarkers, 2023 & 2031 (%)

Figure 38 Europe Breast Cancer Liquid Biopsy Market Share, By Application, 2023 & 2031 (%)

Figure 39 Europe Breast Cancer Liquid Biopsy Market Share, By End-User, 2023 & 2031 (%)

Figure 40 Europe Breast Cancer Liquid Biopsy Market Share, By Country, 2023 & 2031 (%)

Figure 41 Asia-Pacific Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 42 Asia-Pacific Breast Cancer Liquid Biopsy Market Share, By Product Type, 2023 & 2031 (%)

Figure 43 Asia-Pacific Breast Cancer Liquid Biopsy Market Share, By Circulating Biomarkers, 2023 & 2031 (%)

Figure 44 Asia-Pacific Breast Cancer Liquid Biopsy Market Share, By Application, 2023 & 2031 (%)

Figure 45 Asia-Pacific Breast Cancer Liquid Biopsy Market Share, By End-User, 2023 & 2031 (%)

Figure 46 Asia-Pacific Breast Cancer Liquid Biopsy Market Share, By Country, 2023 & 2031 (%)

Figure 47 Middle East and Africa Breast Cancer Liquid Biopsy Market Value, 2022-2031 (US$ Million)

Figure 48 Middle East and Africa Breast Cancer Liquid Biopsy Market Share, By Product Type, 2023 & 2031 (%)

Figure 49 Middle East and Africa Breast Cancer Liquid Biopsy Market Share, By Circulating Biomarkers, 2023 & 2031 (%)

Figure 50 Middle East and Africa Breast Cancer Liquid Biopsy Market Share, By Application, 2023 & 2031 (%)

Figure 51 Middle East and Africa Breast Cancer Liquid Biopsy Market Share, By End-User, 2023 & 2031 (%)

Figure 52 F. Hoffmann-La Roche Ltd: Financials

Figure 53 Thermo Fisher Scientific Inc.: Financials

Figure 54 Abbott: Financials

Figure 55 Agilent Technologies Inc.: Financials

Figure 56 Merck KGaA: Financials

Figure 57 Cell Signaling Technology Inc.: Financials

Figure 58 Medtronic: Financials

Figure 59 Bio-Rad Laboratories Inc.: Financials

Figure 60 ExoDx: Financials

Figure 61 Biocept Inc.: Financials

글로벌 유방암 액체 생검 시장 – 2024년 – 2031년

Global Breast Cancer Liquid Biopsy Market - 2024 - 2031